Should I buy or sell Inhibrx stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INBX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INBX, but not buy additional shares or sell existing shares. View INBX analyst ratings or view top-rated stocks .

What is Inhibrx's stock price target for 2024?

2 analysts have issued 1 year target prices for Inhibrx's stock. Their INBX share price targets range from $27.00 to $27.00. On average, they anticipate the company's stock price to reach $27.00 in the next twelve months. This suggests that the stock has a possible downside of 21.6%. View analysts price targets for INBX or view top-rated stocks among Wall Street analysts .

How have INBX shares performed in 2024?

Inhibrx's stock was trading at $38.00 on January 1st, 2024. Since then, INBX shares have decreased by 9.3% and is now trading at $34.45. View the best growth stocks for 2024 here .

Are investors shorting Inhibrx?

Inhibrx saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,150,000 shares, an increase of 34.4% from the March 15th total of 1,600,000 shares. Based on an average daily trading volume, of 726,500 shares, the days-to-cover ratio is currently 3.0 days. Currently, 6.0% of the company's shares are sold short. View Inhibrx's Short Interest .

When is Inhibrx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our INBX earnings forecast .

How were Inhibrx's earnings last quarter?

Inhibrx, Inc. (NASDAQ:INBX) announced its quarterly earnings data on Wednesday, February, 28th. The company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by $0.66. The company earned $1.63 million during the quarter, compared to the consensus estimate of $0.10 million. Inhibrx had a negative net margin of 13,408.95% and a negative trailing twelve-month return on equity of 590.78%.

What ETFs hold Inhibrx's stock?

ETFs with the largest weight of Inhibrx (NASDAQ:INBX) stock in their portfolio include ProShares Merger ETF (MRGR) , ALPS Medical Breakthroughs ETF (SBIO) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) and IQ Merger Arbitrage ETF (MNA) . iShares Micro-Cap ETF (IWC) .

What other stocks do shareholders of Inhibrx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD) , Trevena (TRVN) , Vivint Solar (VSLR) , Activision Blizzard (ATVI) , Daqo New Energy (DQ) , Fastly (FSLY) , Innovative Industrial Properties (IIPR) , Lovesac (LOVE) and Micron Technology (MU) .

When did Inhibrx IPO?

Inhibrx (INBX) raised $102 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.

Who are Inhibrx's major shareholders?

Inhibrx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.06%). Insiders that own company stock include Brendan P Eckelman , Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe. View institutional ownership trends .

How do I buy shares of Inhibrx?

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:INBX

Inhibrx (INBX) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free INBX Stock Alerts

$34.45

-0.16 (-0.46%)

(As of 04/18/2024 ET)

Compare

Today's Range: $34.45
▼
$34.83
50-Day Range: $34.61
▼
$39.56
52-Week Range: $14.31
▼
$39.79

Volume: 415,786 shs
Average Volume: 698,410 shs
Market Capitalization: $1.63 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.00

Get Inhibrx alerts:

Inhibrx MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 21.6% Downside
$27.00 Price Target
Short Interest: Bearish
6.04% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.21
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.35 out of 5 stars

Medical Sector

724th out of 918 stocks

Biotechnology Industry

25th out of 43 stocks

1.0

Analyst's Opinion

Consensus Rating
Inhibrx has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Inhibrx has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.04% of the float of Inhibrx has been sold short.
Short Interest Ratio / Days to Cover
Inhibrx has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Inhibrx has recently increased by 34.38%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Inhibrx does not currently pay a dividend.
Dividend Growth
Inhibrx does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Inhibrx has received a 71.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for deficiency diseases", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Inhibrx is -1.21.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Inhibrx this week, compared to 1 article on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inhibrx insiders have not sold or bought any company stock.
Percentage Held by Insiders
22.20% of the stock of Inhibrx is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
82.46% of the stock of Inhibrx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Inhibrx is -6.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Inhibrx is -6.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Inhibrx has a P/B Ratio of 37.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Inhibrx Stock (NASDAQ:INBX)

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

INBX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INBX Stock News Headlines

April 16, 2024 | msn.com

As more rare disease therapies launch, their prices are rising

March 16, 2024 | finance.yahoo.com

INBX Apr 2024 50.000 put

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

March 16, 2024 | finance.yahoo.com

INBX Apr 2024 55.000 call

February 29, 2024 | realmoney.thestreet.com

Inhibrx just downgraded at Jefferies, here's why

February 28, 2024 | finanznachrichten.de

Inhibrx, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

February 28, 2024 | prnewswire.com

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

February 10, 2024 | businesswire.com

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

April 18, 2024 | Paradigm Press (Ad)

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

February 10, 2024 | businesswire.com

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

January 24, 2024 | msn.com

Sanofi signs agreement to acquire Inhibrx for $1.7bn

January 24, 2024 | finance.yahoo.com

Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More

January 24, 2024 | seekingalpha.com

Sanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 Acquisition

January 24, 2024 | finance.yahoo.com

Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?

January 24, 2024 | realmoney.thestreet.com

Inhibrx just downgraded at LifeSci Capital, here's why

January 23, 2024 | msn.com

These Stocks Are Moving the Most Today: United, Logitech, Archer Daniels, Inhibrx, J&J, Netflix, and More

January 23, 2024 | marketwatch.com

Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update

January 23, 2024 | reuters.com

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

January 23, 2024 | tmcnet.com

INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders

December 9, 2023 | morningstar.com

Inhibrx Inc Ordinary Shares INBX

December 2, 2023 | morningstar.com

Inhibrx Inc Ordinary Shares

November 10, 2023 | msn.com

Inhibrx posts Q3 results

November 10, 2023 | finanznachrichten.de

Inhibrx, Inc.: Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

November 9, 2023 | finance.yahoo.com

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

November 4, 2023 | msn.com

Inhibrx reports initial Phase I Ewing sarcoma trial data

November 2, 2023 | finance.yahoo.com

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

September 19, 2023 | finance.yahoo.com

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

See More Headlines

Receive INBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:INBX
CUSIP: N/A
CIK: 1739614
Web: www.inhibrx.com
Phone: 858-795-4220
Fax: N/A
Employees: 166
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $27.00
High Stock Price Target: $27.00
Low Stock Price Target: $27.00
Potential Upside/Downside: -22.0%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-241,360,000.00
Net Margins: -13,408.95%
Pretax Margin: -13,318.00%
Return on Equity: -590.78%
Return on Assets: -84.13%

Debt

Debt-to-Equity Ratio: 4.78
Current Ratio: 5.24
Quick Ratio: 5.25

Sales & Book Value

Annual Sales: $1.80 million
Price / Sales: 910.94
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.92 per share
Price / Book: 37.61

Miscellaneous

Outstanding Shares: 47,390,000
Free Float: 36,871,000
Market Cap: $1.64 billion
Optionable: Optionable
Beta: 2.91

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Mark Paul Lappe (Age 56)
Founder, Chairman, President & CEO
Comp: $1.1M
Dr. Brendan P. Eckelman Ph.D. (Age 44)
Founder & Chief Scientific Officer
Comp: $769.25k
Ms. Kelly Devine Deck B.S. (Age 43)
CPA, M.S., Executive VP & CFO
Comp: $636.87k
Mr. Quinn L. Deveraux
Founder
Dr. Ashraf Amanullah (Age 56)
Executive VP & Chief Technical Operations Officer
Ms. Leah Pollema J.D.
VP, Corporate Secretary & General Counsel
Dr. Charbel Helaihel Pharm.D.
Vice President of Marketing & Commercial Planning
Mr. Jeffrey J. Jensen
Executive VP & Chief Clinical Operations Officer
Mr. David Matly M.B.A.
Executive VP and Chief Commercial & Business Development Officer
Dr. Carlos Bais Ph.D.
Executive Vice President of Translational Sciences

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Inhibrx stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INBX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INBX, but not buy additional shares or sell existing shares.
View INBX analyst ratings or view top-rated stocks.
What is Inhibrx's stock price target for 2024?: 2 analysts have issued 1 year target prices for Inhibrx's stock. Their INBX share price targets range from $27.00 to $27.00. On average, they anticipate the company's stock price to reach $27.00 in the next twelve months. This suggests that the stock has a possible downside of 21.6%.
View analysts price targets for INBX or view top-rated stocks among Wall Street analysts.
How have INBX shares performed in 2024?: Inhibrx's stock was trading at $38.00 on January 1st, 2024. Since then, INBX shares have decreased by 9.3% and is now trading at $34.45.
View the best growth stocks for 2024 here.
Are investors shorting Inhibrx?: Inhibrx saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,150,000 shares, an increase of 34.4% from the March 15th total of 1,600,000 shares. Based on an average daily trading volume, of 726,500 shares, the days-to-cover ratio is currently 3.0 days. Currently, 6.0% of the company's shares are sold short.
View Inhibrx's Short Interest.
When is Inhibrx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our INBX earnings forecast.
How were Inhibrx's earnings last quarter?: Inhibrx, Inc. (NASDAQ:INBX) announced its quarterly earnings data on Wednesday, February, 28th. The company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by $0.66. The company earned $1.63 million during the quarter, compared to the consensus estimate of $0.10 million. Inhibrx had a negative net margin of 13,408.95% and a negative trailing twelve-month return on equity of 590.78%.

What ETFs hold Inhibrx's stock?: ETFs with the largest weight of Inhibrx (NASDAQ:INBX) stock in their portfolio include ProShares Merger ETF (MRGR), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and IQ Merger Arbitrage ETF (MNA).iShares Micro-Cap ETF (IWC).
What other stocks do shareholders of Inhibrx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU).
When did Inhibrx IPO?: Inhibrx (INBX) raised $102 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse acted as the underwriters for the IPO and LifeSci Capital was co-manager.
Who are Inhibrx's major shareholders?: Inhibrx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.06%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe.
View institutional ownership trends.
How do I buy shares of Inhibrx?: Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INBX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Inhibrx (INBX) Stock Price, News & Analysis

Inhibrx MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

Company Ownership

Earnings and Valuation

About Inhibrx Stock (NASDAQ:INBX)

INBX Stock Price History

INBX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

INBX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™